人类免疫缺陷病毒蛋白酶抑制剂洛匹那韦和利托那韦的水溶性前药。

Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

作者信息

DeGoey David A, Grampovnik David J, Flosi William J, Marsh Kennan C, Wang Xiu C, Klein Larry L, McDaniel Keith F, Liu Yaya, Long Michelle A, Kati Warren M, Molla Akhteruzzaman, Kempf Dale J

机构信息

Antiviral Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA.

出版信息

J Med Chem. 2009 May 14;52(9):2964-70. doi: 10.1021/jm900080g.

Abstract

We studied the synthesis, cleavage rates, and oral administration of prodrugs of the HIV protease inhibitors (PIs) lopinavir and ritonavir. Phosphate esters attached directly to the central hydroxyl groups of these PIs did not demonstrate enzyme-mediated cleavage in vitro and did not provide measurable plasma levels of the parent drugs in vivo. However, oxymethylphosphate (OMP) and oxyethylphosphate (OEP) prodrugs provided improved rates of cleavage, high levels of aqueous solubility, and high plasma levels of the parent drugs when dosed orally in rats and dogs. Dosing unformulated capsules containing the solid prodrugs led to plasma levels equivalent to those observed for dosing formulated solutions of the parent drugs. A direct synthetic process for the preparation of OMP and OEP prodrugs was developed, and the improved synthetic method may be applicable to the preparation of analogous soluble prodrugs of other drug classes with limited solubility.

摘要

我们研究了HIV蛋白酶抑制剂(PIs)洛匹那韦和利托那韦前药的合成、裂解速率及口服给药情况。直接连接到这些PIs中心羟基上的磷酸酯在体外未表现出酶介导的裂解,且在体内未产生可测量的母体药物血浆水平。然而,氧甲基磷酸酯(OMP)和氧乙基磷酸酯(OEP)前药在大鼠和犬口服给药时,具有更高的裂解速率、高水溶性以及母体药物的高血浆水平。给大鼠和犬灌胃含有固体前药的未配方胶囊,所产生的血浆水平与给母体药物的配方溶液灌胃时观察到的水平相当。我们开发了一种制备OMP和OEP前药的直接合成方法,这种改进的合成方法可能适用于制备其他溶解度有限的药物类别的类似可溶性前药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索